Perspective Therapeutics (CATX) 10-Q 4 May 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2018	May 02, 2018
Document Information [Line Items]
Entity Registrant Name	IsoRay, Inc.
Entity Central Index Key	728,387
Trading Symbol	isr
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		55,100,229
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2018	Jun. 30, 2017
Current assets:
Cash and cash equivalents	$ 2,365	$ 5,932
Certificates of deposit (Note 3)	2,150	3,039
Accounts receivable, net of allowance for doubtful accounts of $26 and $26, respectively	970	726
Inventory	458	323
Prepaid expenses and other current assets	382	271
Total current assets	6,325	10,291
Property and equipment, net	1,229	1,054
Restricted cash	181	181
Inventory, non-current	395	513
Other assets, net of accumulated amortization	192	230
Total assets	8,322	12,269
Current liabilities:
Accounts payable and accrued expenses	773	630
Accrued protocol expense	77	75
Accrued radioactive waste disposal	28	125
Accrued payroll and related taxes	105	138
Accrued vacation	140	138
Total current liabilities	1,123	1,106
Long-term liabilities:
Asset retirement obligation	583	561
Total liabilities	1,706	1,667
Commitments and contingencies (Note 8)
Shareholders' equity:
Common stock, $.001 par value; 192,998,329 shares authorized; 55,100,229 and 55,017,419 shares issued and outstanding	55	55
Additional paid-in capital	83,507	83,151
Accumulated deficit	(76,946)	(72,604)
Total shareholders' equity	6,616	10,602
Total liabilities and shareholders' equity	8,322	12,269
Series A Preferred Stock [Member]
Shareholders' equity:
Preferred stock, value, issued	0	0
Series B Preferred Stock [Member]
Shareholders' equity:
Preferred stock, value, issued	0	0
Series C Preferred Stock [Member]
Shareholders' equity:
Preferred stock, value, issued	0	0
Series D Preferred Stock [Member]
Shareholders' equity:
Preferred stock, value, issued	$ 0	$ 0

Consolidated Balance Sheets (C3

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2018	Jun. 30, 2017
Allowance for doubtful accounts receivable, current	$ 26	$ 26
Preferred stock, shares authorized (in shares)	7,001,671	7,001,671
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	192,998,329	192,998,329
Common stock, shares issued (in shares)	55,100,229	55,017,419
Common stock, shares outstanding (in shares)	55,100,229	55,017,419
Series A Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series B Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	59,065	59,065
Preferred stock, shares outstanding (in shares)	59,065	59,065
Series C Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series D Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	1,671	1,671
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Product sales, net	$ 1,573	$ 1,282	$ 4,320	$ 3,391
Cost of product sales	964	989	2,915	3,051
Gross profit	609	293	1,405	340
Research and development
Proprietary research and development	317	166	914	488
Collaboration arrangement, net of reimbursement (Note 8)	156	161	260	161
Total research and development	473	327	1,174	649
Sales and marketing	692	530	1,980	1,550
General and administrative	783	825	2,610	2,632
Change in estimate of asset retirement obligation				(48)
Total operating expenses	1,948	1,682	5,764	4,783
Operating loss	(1,339)	(1,389)	(4,359)	(4,443)
Non-operating income:
Interest income, net	7	29	17	89
Change in fair value of warrant derivative liability				27
Other income				20
Non-operating income, net	7	29	17	136
Net loss	(1,332)	(1,360)	(4,342)	(4,307)
Preferred stock dividends	(3)	(3)	(8)	(8)
Net loss applicable to common shareholders	$ (1,335)	$ (1,363)	$ (4,350)	$ (4,315)
Basic and diluted loss per share (in dollars per share)	$ (0.02)	$ (0.02)	$ (0.08)	$ (0.08)
Weighted average shares used in computing net loss per share:
Basic and diluted (in shares)	55,100	55,017	55,058	55,015

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,342)	$ (4,307)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation expense	56	50
Loss on equipment disposals		5
Amortization of other assets	37	35
Change in fair value of warrant derivative liability		(27)
Accretion of asset retirement obligation	22	22
Change in estimate of asset retirement obligation		(48)
Share-based compensation	317	162
Changes in operating assets and liabilities:
Accounts receivable, gross	(250)	(249)
Inventory	(16)	54
Prepaid expenses and other current assets	(58)	(44)
Accounts payable and accrued expenses	96	(104)
Accrued protocol expense	2	(38)
Accrued radioactive waste disposal	(97)	26
Accrued payroll and related taxes	(33)	(47)
Accrued vacation	2	11
Net cash used by operating activities	(4,264)	(4,499)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment	(231)	(293)
Additions to other assets		(151)
Proceeds from maturity of certificates of deposit	4,943
Purchases of and interest from certificates of deposit	(4,054)	(87)
Net cash provided (used) by investing activities	658	(531)
CASH FLOWS FROM FINANCING ACTIVITIES:
Preferred dividends paid	(11)	(11)
Proceeds from sales of common stock, pursuant to exercise of options	50	2
Net cash provided (used) by financing activities	39	(9)
Net decrease in cash and cash equivalents	(3,567)	(5,039)
Cash and cash equivalents, beginning of period	5,932	10,139
CASH AND CASH EQUIVALENTS, END OF PERIOD	2,365	5,100
Non-cash investing and financing activities:
Land acquired with accounts payable		$ 198

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	9 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1. Basis of Presentation The accompanying unaudited interim consolidated financial statements are those of IsoRay, Inc., and its wholly-owned subsidiaries referred to herein as “IsoRay” or the “Company”. All significant intercompany accounts and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments necessary for the fair presentation of the consolidated financial statements have been included. These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related footnotes as set forth in the Company’s annual report filed on Form 10 June 30, 2017. The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information not Certain prior period amounts have been reclassified to conform to the current period’s presentation. The results of operations for the periods presented may not may 2018 0%.

Note 2 - New Accounting Pronoun

Note 2 - New Accounting Pronouncements	9 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	2. New Accounting Pronouncements In May 2014, No. 2014 09 605 10 five first 2019, first 2018. first 2019 2014 09 not In July 2015, No. 2015 11: December 15, 2016. July 1, 2017. not In November 2015, 2015 17 July 1, 2017. not In February 2016, 2016 02 842 December 15, 2018. first 2020. In August 2016, No. 2016 15 230 eight December 15, 2017, Other accounting standards that have been issued or proposed by FASB that do not not not not

Note 3 - Certificates of Deposi

Note 3 - Certificates of Deposit	9 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Cost-method Investments, Description [Text Block]	3. Certificates of Deposit Certificate of Deposit Account Registry Service (CDARS) is a system that allows the Company to invest in certificates of deposit through a single financial institution that exceed the $250,000 March 31, 2018 June 30, 2017 As of March 31, 2018 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year CDARS $ 1,325 $ 825 $ - $ - As of June 30, 2017 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year CDARS $ 3,039 $ - $ - $ -

Note 4 - Loss Per Share

Note 4 - Loss Per Share	9 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	4. Loss per Share Basic and diluted earnings (loss) per share are calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding, and does not March 31, 2018 2017, not Securities not March 31, 2018 2017, March 31, 2018 2017 Series B preferred stock 59 59 Common stock warrants 250 5 Common stock options 3,272 2,456 Total potential dilutive securities 3,581 2,520

Note 5 - Inventory

Note 5 - Inventory	9 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Inventory Disclosure [Text Block]	5. Inventory Inventory consisted of the following at March 31, 2018 June 30, 2017 ( March 31, June 30, 2018 2017 Raw materials $ 287 $ 191 Work in process 153 121 Finished goods 18 11 Total inventory, current $ 458 $ 323 March 31, June 30, 2018 2017 Enriched barium, non-current $ 347 $ 470 Raw materials, non-current 48 43 Total inventory, non-current $ 395 $ 513 Inventory, non-current is raw materials that were ordered in quantities to obtain volume cost discounts which based on current and anticipated sales volumes will not On August 25, 2017, 130 November 2017. 131 4,000 131 ten no third 131

Note 6 - Property and Equipment

Note 6 - Property and Equipment	9 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	6. Property and Equipment Property and equipment consisted of the following at March 31, 2018 June 30, 2017 ( March 31, June 30, 2018 2017 Land $ 366 $ 366 Equipment 3,806 3,776 Leasehold improvements 4,136 4,130 Other 1 568 373 Property and equipment 8,876 8,645 Less accumulated depreciation (7,647 ) (7,591 ) Property and equipment, net $ 1,229 $ 1,054 1 March 31, 2018 June 30, 2017

Note 7 - Share-based Compensati

Note 7 - Share-based Compensation	9 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	7. Share-Based Compensation The following table presents the share-based compensation expense recognized for stock-based options during the three March 31, 2018 2017 Three Months 2018 2017 Cost of product sales $ 10 $ 15 Research and development expenses 20 13 Sales and marketing expenses 17 9 General and administrative expenses 30 3 Total share-based compensation $ 77 $ 40 The following table presents the share-based compensation expense recognized for stock-based options during the nine March 31, 2018 2017 Nine Months 2018 2017 Cost of product sales $ 40 $ 59 Research and development expenses 58 28 Sales and marketing expenses 50 35 General and administrative expenses 97 40 Total share-based compensation $ 245 $ 162 As of March 31, 2018, $622,000 1.16 A summary of stock options within the Company’s share-based compensation plans as of March 31, 2018 Weighted Weighted Average Number of Exercise Contractual Intrinsic As of March 31, 2018 Options Price Term (Years) Value Outstanding 3,272 $ .76 7.14 $ 41 Vested and expected to vest 3,172 $ .76 7.08 $ 41 Vested and exercisable 1,742 $ .91 5.25 $ 41 There were no three March 31, 2018 2017, There were 15,000 10,000 $5,000 $4,000 three March 31, 2018 2017, There were no 22,500 three March 31, 2018 2017, There were 37,500 96,432 three March 31, 2018 2017, There were 82,810 6,800 nil $3,000 nine March 31, 2018 2017, There were 90,000 20,000 $38,000 $7,700 nine March 31, 2018 2017, There were no 303,034 nine March 31, 2018 2017, There were 114,041 179,437 nine March 31, 2018 2017,

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	9 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. Commitments and Contingencies Isotope Purchase Agreement In December 2015, 131 one 131. March 31, 2017, December 2016 December 31, 2017. October 23, 2017, 131 December 31, 2018. Research and Development - Collaborative Arrangement On March 13, 2017, November 8, 2016 March 31, 2018, 2018 fourth 808 October 2017. During the three March 31, 2018 2017, $304,000 $322,000, During the nine March 31, 2018 2017, $509,000 $322,000, As of March 31, 2018 June 30, 2017, $73,000 $66,000 Derivative Complaint related to Shareholder Value On September 29, 2016, No. 0:16 03297 131 not On November 17, 2016, not January 23, 2017. March 9, 2017. April 20, 2017, May 17, 2017. August 22, 2017, October 19, 2017, Media Advertising Agreement On October 3, 2017, Pursuant to the Agreement, Al & J was to introduce IsoRay to potential sources of media, marketing agreements, and/or strategic alliances, including but not not On December 29, 2017, no As compensation for the services provided prior to termination, IsoRay paid Al & J $60,000 250,000 October 3, 2020, $0.54 12.

Note 9 - Fair Value Measurement

Note 9 - Fair Value Measurements	9 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	9. Fair Value Measurements The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement (in thousands): Fair Value at March 31, 2018 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 2,365 $ 2,365 $ - $ - Fair Value at June 30, 2017 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 5,932 $ 5,932 $ - $ - The Company’s cash and cash equivalent instruments are classified within Level 1

Note 10 - Related Party Transac

Note 10 - Related Party Transactions	9 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	10. Related Party Transactions During the quarter ended June 30, 2016, 1/3 nine March 31, 2017, $20,000 No nine March 31, 2018.

Note 11 - Concentrations of Cre

Note 11 - Concentrations of Credit and Other Risks	9 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	11. Concentrations of Credit and Other Risks One group of customers, facilities or physician practices has revenues that aggregate to greater than 10% Nine months ended March 31, March 31, Facility 2018 2017 El Camino Hospital of Los Gatos, Fremont Surgery Center & other facilities 1 24.23 % 22.76 % 1 10% one The Company routinely assesses the financial strength of its customers and provides an allowance for doubtful accounts as necessary.

Note 12 - Shareholders' Equity

Note 12 - Shareholders' Equity	9 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	1 2 . Shareholders’ Equity Warrants On October 3, 2017, 250,000 October 3, 2020, $0.54 $72,000 nine March 31, 2018. December 29, 2017, The key assumptions used in the Black-Scholes valuation model to calculate the fair value of the warrants are as follows: October 3, 2017 Grant date fair value $ 0.2874 Options issued 250,000 Exercise price $ 0.54 Expected term (in years) 3 Risk-free rate 1.62 % Volatility 81.66 % The following table summarizes all warrants outstanding as of the beginning of the fiscal year, all activity related to warrants issued, cancelled, exercised or expired during the period and weighted average prices by category. Weighted average Warrants exercise price Outstanding as of June 30, 2017 - $ - Warrants issued 250,000 $ 0.54 Outstanding as of March 31, 2018 250,000 $ 0.54 The following table summarizes additional information about the Company’s common warrants outstanding as of March 31, 2018: Number of Warrants Exercise Price¹ Expiration Date 250,000 $ 0.54 October 2020 1

Note 3 - Certificates of Depo18

Note 3 - Certificates of Deposit (Tables)	9 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Cost Method Investments [Table Text Block]	As of March 31, 2018 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year CDARS $ 1,325 $ 825 $ - $ - As of June 30, 2017 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year CDARS $ 3,039 $ - $ - $ -

Note 4 - Loss Per Share (Tables

Note 4 - Loss Per Share (Tables)	9 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	March 31, 2018 2017 Series B preferred stock 59 59 Common stock warrants 250 5 Common stock options 3,272 2,456 Total potential dilutive securities 3,581 2,520

Note 5 - Inventory (Tables)

Note 5 - Inventory (Tables)	9 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, June 30, 2018 2017 Raw materials $ 287 $ 191 Work in process 153 121 Finished goods 18 11 Total inventory, current $ 458 $ 323
Schedule of Inventory, Noncurrent [Table Text Block]	March 31, June 30, 2018 2017 Enriched barium, non-current $ 347 $ 470 Raw materials, non-current 48 43 Total inventory, non-current $ 395 $ 513

Note 6 - Property and Equipme21

Note 6 - Property and Equipment (Tables)	9 Months Ended
	Mar. 31, 2018
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, June 30, 2018 2017 Land $ 366 $ 366 Equipment 3,806 3,776 Leasehold improvements 4,136 4,130 Other 1 568 373 Property and equipment 8,876 8,645 Less accumulated depreciation (7,647 ) (7,591 ) Property and equipment, net $ 1,229 $ 1,054

Note 7 - Share-based Compensa22

Note 7 - Share-based Compensation (Tables)	9 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months 2018 2017 Cost of product sales $ 10 $ 15 Research and development expenses 20 13 Sales and marketing expenses 17 9 General and administrative expenses 30 3 Total share-based compensation $ 77 $ 40 Nine Months 2018 2017 Cost of product sales $ 40 $ 59 Research and development expenses 58 28 Sales and marketing expenses 50 35 General and administrative expenses 97 40 Total share-based compensation $ 245 $ 162
Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	Weighted Weighted Average Number of Exercise Contractual Intrinsic As of March 31, 2018 Options Price Term (Years) Value Outstanding 3,272 $ .76 7.14 $ 41 Vested and expected to vest 3,172 $ .76 7.08 $ 41 Vested and exercisable 1,742 $ .91 5.25 $ 41

Note 9 - Fair Value Measureme23

Note 9 - Fair Value Measurements (Tables)	9 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value at March 31, 2018 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 2,365 $ 2,365 $ - $ - Fair Value at June 30, 2017 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 5,932 $ 5,932 $ - $ -

Note 11 - Concentrations of C24

Note 11 - Concentrations of Credit and Other Risks (Tables)	9 Months Ended
	Mar. 31, 2018
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Nine months ended March 31, March 31, Facility 2018 2017 El Camino Hospital of Los Gatos, Fremont Surgery Center & other facilities 1 24.23 % 22.76 %

Note 12 - Shareholders' Equity

Note 12 - Shareholders' Equity (Tables)	9 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Share-based Payment Award, Warrants, Valuation Assumptions [Table Text Block]	October 3, 2017 Grant date fair value $ 0.2874 Options issued 250,000 Exercise price $ 0.54 Expected term (in years) 3 Risk-free rate 1.62 % Volatility 81.66 %
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Weighted average Warrants exercise price Outstanding as of June 30, 2017 - $ - Warrants issued 250,000 $ 0.54 Outstanding as of March 31, 2018 250,000 $ 0.54
Schedule of Stockholders Equity Note Warrants or Rights By Exercise Price Range [Table Text Block]	Number of Warrants Exercise Price¹ Expiration Date 250,000 $ 0.54 October 2020

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation (Details Textual)	9 Months Ended
	Mar. 31, 2018
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%

Note 3 - Certificates of Depo27

Note 3 - Certificates of Deposit - Summary of Certificates of Deposit (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Jun. 30, 2017
Under 90 Days [Member]
CDARS	$ 1,325	$ 3,039
For 91 Days to Six Months [Member]
CDARS	825
Six Months to 1 Year [Member]
CDARS
Greater than 1 Year [Member]
CDARS

Note 4 - Loss Per Share - Antid

Note 4 - Loss Per Share - Antidilutive Securities (Details) - shares shares in Thousands	9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Antidilutive securities (in shares)	3,581	2,520
Series B Preferred Stock [Member]
Antidilutive securities (in shares)	59	59
Warrant [Member]
Antidilutive securities (in shares)	250	5
Employee Stock Option [Member]
Antidilutive securities (in shares)	3,272	2,456

Note 5 - Inventory - Current In

Note 5 - Inventory - Current Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Jun. 30, 2017
Raw materials	$ 287	$ 191
Work in process	153	121
Finished goods	18	11
Total inventory, current	$ 458	$ 323

Note 5 - Inventory - Noncurrent

Note 5 - Inventory - Noncurrent Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Jun. 30, 2017
Total inventory, non-current	$ 395	$ 513
Enriched Barium Inventory [Member]
Total inventory, non-current	347	470
Raw Materials [Member]
Total inventory, non-current	$ 48	$ 43

Note 6 - Property and Equipme31

Note 6 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands		Mar. 31, 2018	Jun. 30, 2017
Property and equipment, gross		$ 8,876	$ 8,645
Less accumulated depreciation		(7,647)	(7,591)
Property and equipment, net		1,229	1,054
Land [Member]
Property and equipment, gross		366	366
Equipment [Member]
Property and equipment, gross		3,806	3,776
Leasehold Improvements [Member]
Property and equipment, gross		4,136	4,130
Other [Member]
Property and equipment, gross	[1]	$ 568	$ 373
[1]	Represents items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet. Also included at March 31, 2018 and June 30, 2017 are costs associated with automation of production processes and advance planning and design work on the Company's new production facility.

Note 7 - Share-based Compensa32

Note 7 - Share-based Compensation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 622,000		$ 622,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			1 year 58 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	0	0	82,810	6,800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	15,000	10,000	90,000	20,000
Share-based Compensation Arrangement By Share-based Payment Award Options Grants in Period Fair Value	$ 5,000	$ 4,000	$ 38,000	$ 7,700
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	0	22,500	0	303,034
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	37,500	96,432	114,041	179,437
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value			$ 0	$ 3,000

Note 7 - Share-based Compensa33

Note 7 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Total share-based compensation	$ 77	$ 40	$ 245	$ 162
Cost of Sales [Member]
Total share-based compensation	10	15	40	59
Research and Development Expense [Member]
Total share-based compensation	20	13	58	28
Selling and Marketing Expense [Member]
Total share-based compensation	17	9	50	35
General and Administrative Expense [Member]
Total share-based compensation	$ 30	$ 3	$ 97	$ 40

Note 7 - Share-based Compensa34

Note 7 - Share-based Compensation - Summary of Stock Options (Details) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Mar. 31, 2018USD ($)$ / sharesshares
Outstanding, options (in shares) | shares	3,272
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 0.76
Outstanding, weighted average contractual term (Year)	7 years 51 days
Outstanding, intrinsic value | $	$ 41
Vested and expected to vest, options (in shares) | shares	3,172
Vested and expected to vest, weighted average exercise price (in dollars per share) | $ / shares	$ 0.76
Vested and expected to vest, weighted average contractual term (Year)	7 years 29 days
Vested and expected to vest, intrinsic value | $	$ 41
Vested and exercisable, options (in shares) | shares	1,742
Vested and exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 0.91
Vested and exercisable, weighted average contractual term (Year)	5 years 91 days
Vested and exercisable, intrinsic value | $	$ 41

Note 8 - Commitments and Cont35

Note 8 - Commitments and Contingencies (Details Textual) - USD ($)	Oct. 03, 2017	Mar. 31, 2018		Mar. 31, 2017	Mar. 31, 2018		Mar. 31, 2017	Jun. 30, 2017
Research and Development Expense, Total		$ 473,000		$ 327,000	$ 1,174,000		$ 649,000
Receivables, Net, Current, Total		$ 970,000			$ 970,000			$ 726,000
Class of Warrant or Right, Issued for Services					250,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.54	[1]		$ 0.54	[1]
Al & J Media [Member]
Payments for Advertising Services	$ 60,000
Class of Warrant or Right, Issued for Services	250,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.54
Collaborative Development Agreement [Member]
Research and Development Expense, Total		$ 304,000		$ 322,000	$ 509,000		$ 322,000
Collaborative Development Agreement [Member] | GammaTile LLC [Member] | Prepaid Expenses and Other Current Assets [Member]
Receivables, Net, Current, Total		$ 73,000			$ 73,000			$ 66,000
[1]	Exercise prices have been rounded to the nearest whole cent.

Note 9 - Fair Value Measureme36

Note 9 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2018	Jun. 30, 2017
Cash and cash equivalents	$ 2,365	$ 5,932
Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents	2,365	5,932
Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents
Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents

Note 10 - Related Party Trans37

Note 10 - Related Party Transactions (Details Textual) - USD ($)	9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Go Intellectual Capital LLC [Member]
Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party	$ 0	$ 20,000

Note 11 - Concentrations of C38

Note 11 - Concentrations of Credit and Other Risks - Revenue Concentration (Details)		9 Months Ended
		Mar. 31, 2018	Mar. 31, 2017
Sales Revenue, Goods, Net [Member]
El Camino Hospital of Los Gatos, Fremont Surgery Center & other facilities	[1]	24.23%	22.76%
[1]	This group of facilities individually each comprise less than 10% of total Company product sales. They are serviced by the same physician group, one of whom is our Medical Director.

Note 12 - Shareholders' Equit39

Note 12 - Shareholders' Equity (Details Textual) - USD ($)	Oct. 03, 2017	Mar. 31, 2018		Mar. 31, 2017	Mar. 31, 2018		Mar. 31, 2017	Jun. 30, 2017
Class of Warrant or Right, Issued for Services					250,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.54	[1]		$ 0.54	[1]
Allocated Share-based Compensation Expense, Total		$ 77,000		$ 40,000	$ 245,000		$ 162,000
Warrant [Member]
Class of Warrant or Right, Issued for Services	250,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.54
Al & J Media [Member]
Class of Warrant or Right, Issued for Services	250,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.54
Al & J Media [Member] | Warrant [Member]
Allocated Share-based Compensation Expense, Total					$ 72,000
[1]	Exercise prices have been rounded to the nearest whole cent.

Note 12 - Shareholders' Equit40

Note 12 - Shareholders' Equity - Fair Value Assumptions (Details) - $ / shares	Oct. 03, 2017	Mar. 31, 2018		Jun. 30, 2017
Options issued (in shares)		250,000
Exercise Price (in dollars per share)		$ 0.54	[1]
Warrant [Member]
Grant date fair value (in dollars per share)	$ 0.2874
Options issued (in shares)	250,000
Exercise Price (in dollars per share)	$ 0.54
Expected term (in years) (Year)	3 years
Risk-free rate	1.62%
Volatility	81.66%
[1]	Exercise prices have been rounded to the nearest whole cent.

Note 12 - Shareholders' Equit41

Note 12 - Shareholders' Equity - Warrant Activity (Details)	9 Months Ended
	Mar. 31, 2018$ / sharesshares
Outstanding as of June 30, 2017 (in shares) | shares
Options issued (in shares) | shares	250,000
Outstanding as of March 31, 2018 (in shares) | shares	250,000
Outstanding, as of June 30, 2017, weighted average exercise price (in dollars per share) | $ / shares
Warrants issued, weighted average exercise price (in dollars per share) | $ / shares	0.54
Outstanding, as of March 31, 2018, weighted average exercise price (in dollars per share) | $ / shares	$ 0.54	[1]
[1]	Exercise prices have been rounded to the nearest whole cent.

Note 12 - Shareholders' Equit42

Note 12 - Shareholders' Equity - Warrant Information (Details) - $ / shares	Mar. 31, 2018		Jun. 30, 2017
Exercise Price (in dollars per share)	$ 0.54	[1]
Number of Warrants (in shares)	250,000
[1]	Exercise prices have been rounded to the nearest whole cent.